Abstract. -OBJECTIVE: The present research wants to take a picture of the current epidemiological scenario regarding HCV infection in Italy. Studies used to estimate HCV burden of illness in Italy were so far local and performed a number of years ago, not mirroring the state of the art. EpaC wanted to provide a real number of diagnosed patients, eligible to new anti-HCV therapies.
Introduction
HCV affects an estimated number between 130 million and 210 million people worldwide. According to the European Centre for Disease Prevention and Control, Italy has the highest number of HCV-positive patients in Europe and the highest rate of death from cirrhosis and HCC (1) . Nevertheless, studies used to estimate HCV burden of illness in Italy were so far local and old (performed in 1990s), not mirroring the current state of the art. The Italian epidemiological scenario has changed significantly over the last 20 years. It is important to quantify patients eligible to the new anti-HCV therapies in Italy; however, there are no reliable sources of information on hepatopathic patients prevalence at regional and national level. Two key aspects still recognized as true from old studies were 1) the North-to-South gradient of prevalence (3.9% in Veneto-16.2% in Campania) and 2) an age-related increasing prevalence (from lower values in teenagers and young adults to higher values in adults aged over 60 years) (Figure 1 
Objectives
The present research aims at taking a picture of the up-to-date epidemiological scenario regarding HCV infection in Italy. EpaC wanted to provide Institutions with a real number of diagnosed patients, eligible to the new anti-HCV therapies, as basis for taking aware decisions concerning future HCV eradication strategies and evidence-based budget allocation.
Patients and Methods
A number of Institutional sources were crosschecked. Starting from all regional data regarding HCV-related exemptions (code 016.070.54), a correction/integration was performed with online proforma questionnaire to associated patients (from which we derived patients cured and also other/no exemptions); survey to all prescribing centers in Italy (from which we derived the percentage of patients ineligible to new antiviral treatment); prevalence of particular subpopulations was also collected (prisoners and HIV/HCV coinfected); calculations of new diagnosed, dead and cured patients in 2015. Illegal immigrants and active drug addicts (subpopulations currently rarely cured) were excluded from calculations. Table I . Adjustments on 016 exemption macrocode, applying the national average of subcodes. 1 Adjusted applying the average regional rate of 6 out of 7 Local Health Authorities (LHA) to the lacking LHA (Caserta). 2 Adjusted applying the national average of subcodes, excluding areas with subcodes (0.322%). 3 Adjusted applying the national average of subcodes, excluding areas with subcodes (0.322%) -probable overestimate. 4 Partial data (4 out of 5 LHAs -lacking Reggio Calabria). 5 Adjusted applying the average rate of 2 LHAs (50% of the total regional population) to the other 3 LHAs with macrocodes (data missing from Reggio Calabria). 6 Probable underestimate due to the use of other exemptions. 
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Results
A total of 221,549 patients were derived from regional exemptions databases and the average national prevalence was downsized to 0.364% (Table I) . Adding patients without exemptions/ other exemptions derived from the online survey (Figure 2) , total was 308,624. We deducted the yearly deaths, cured and not eligible patients and, last, integrated with coinfected and prisoners special groups (data not shown). Prevalence was also estimated at regional level, highlighting a reduction of the typical North-to-South prevalence gradient. Applying the abovementioned corrections/integrations, total diagnosed and eligible HCV patients in Italy who can be immediately cured are supposed to range 163,148-187,756 (Table II) .
Discussion
The present research has tried to fill an information gap at national level, which may be of precious help for decision-and policy-makers in defining future therapeutic strategies and budget allocation decisions. In fact, the research provides important information regarding the current HCV epidemiological situation in Italy, which has undergone major changes over the past 10-15 years. According to the results regarding eligible patients, an eradication plan seems to be feasible and applicable in the next few years, also considering the likely price reductions of drugs (about 12,500.00 euros for patient treated, starting from 2018), already estimated by recent studies 3 . We hereby recognize the limits of our research, in particular concerning the estimated numbers co- ming from the survey to prescribing centers and the online proforma questionnaire administered to patients. Specifically, we are aware of possible underestimation of HCV patients with a different exemption code, patients without any exemption, ineligible patients and cured patients without exemptions.
Another important issue to be considered is the current attitude of certain patients cured with generic drugs self-provided through health travels e.g. to India. The number of these "health travellers" seems to be increasing according to recent information come to EpaC's attention.
We intend, therefore, to perform a new research in 2017, which will consider all the above mentioned limits, trying to overcome them and give more precise results.
